The Cooper Companies, Inc. COO Coopersurgical Segment — Net Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Cooper Companies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: The Cooper Companies, Inc.’s 10-Q, filed June 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Cooper Companies, Inc.'s coopersurgical segment — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Cooper Companies, Inc.'s coopersurgical segment — net sales?
- The Cooper Companies, Inc. (COO) reported coopersurgical segment — net sales of $358M in Q1 2026.
- How has The Cooper Companies, Inc.'s coopersurgical segment — net sales changed year-over-year?
- The Cooper Companies, Inc.'s coopersurgical segment — net sales increased by 7.6% year-over-year, from $332.7M to $358M.
- What is the long-term trend for The Cooper Companies, Inc.'s coopersurgical segment — net sales?
- Over 4 years (2021 to 2025), The Cooper Companies, Inc.'s coopersurgical segment — net sales has grown at a 15.0% compound annual growth rate (CAGR), from $770.5M to $1.35B.
- What does coopersurgical segment — net sales mean?
- The total revenue generated by the CooperSurgical business segment from the sale of medical devices and fertility products.
- How do you interpret coopersurgical segment — net sales?
- An increase indicates growing market adoption and successful commercial execution of the surgical and fertility product portfolio, while a decrease may suggest competitive pressure or reduced demand in the medical device market.
- How does coopersurgical segment — net sales compare across companies?
- Comparable to revenue metrics for specialized medical device or reproductive health segments at peer healthcare companies.